Navigation Links
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW

Post-hoc analysis shows nearly nine out of ten patients taking once-daily Lialda remained relapse free at the end of 12 months

WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A long-term phase III, open-label 12-14 month extension study (303) presented at the British Society of Gastroenterology (BSG) meeting in Glasgow, Scotland in March 2007 showed Shire plc's Lialda(mesalamine) is well tolerated in mild to moderate UC patients. Today, secondary endpoints of study 303 were presented as post-hoc analyses at Digestive Disease Week (DDW).

Approved by the FDA on January 16, 2007, for the induction of remission in patients with active, mild to moderate UC, LIALDA is the first and only oral once-daily mesalamine on the market. Safety and effectiveness have been established for up to eight weeks. LIALDA is being evaluated for longer term use.

Long-term remission and relapse rates on LIALDA (abstract # T1296)

A post-hoc analysis of study 303 evaluated maintenance of remission and relapse rates over 12 months. Remission was defined using stringent clinical and endoscopic criteria: modified UC Disease Activity Index (UC-DAI) score of less than or equal to 1, with scores of 0 for rectal bleeding and stool frequency, a combined Physician's Global Assessment and sigmoidoscopy score of less than or equal to 1, with a sigmoidoscopy score reduction of greater than or equal to 1 point from baseline and no mucosal friability. Relapse was defined as withdrawing from the study due to a need for alternative therapy for UC.

Overall, a total of 459 patients entered the maintenance phase of study 303. Of these patients, 362 patients met the stringent remission criteria (clinical and endoscopic as defined above) at baseline (in parent studies 301 and 302 -- LIALDA's eight-week, phase III, placebo-controlled trials that demonstrated efficacy for the induction of remission in active, mild to moderate
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
7. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
10. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
11. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
Post Your Comments:
(Date:5/22/2015)... , May 22, 2015 ... clinical research unit with a worldwide reputation for ... its frequent publications in peer reviewed medical journals. ... stakeholders and regulators in discussions about rules for ...      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical ...
(Date:5/21/2015)... , May 21, 2015 ... has announced the addition of the ... (Ankle Replacement, Digit Replacement, Elbow Replacement, Hip ... to 2019" report to their offering. ... knee replacement was valued at $4,470.9 million ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 ... has announced the addition of the "Market ... and Europe" report to their offering. ,     ... analysis of the respiratory imaging diagnostics market in ... Europe . The service provides ...
Breaking Medicine Technology:North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... devices worldwide, announced today its selected unaudited financial results for ... Highlights for Second Quarter 2011 ... 21.2% over the second quarter of 2010. Robust ...
... Pharmaceutical Company ("the Company," "K-V") (NYSE: KVa/KVb) today announced ... of assets of Nesher Pharmaceuticals, Inc. ("Nesher"), the Company,s ... assets to Zydus Pharmaceuticals (USA), Inc and Zynesher Pharmaceuticals ... sales price for the transaction is $60 million (subject ...
Cached Medicine Technology:Mindray Announces Second Quarter 2011 Financial Results 2Mindray Announces Second Quarter 2011 Financial Results 3Mindray Announces Second Quarter 2011 Financial Results 4Mindray Announces Second Quarter 2011 Financial Results 5Mindray Announces Second Quarter 2011 Financial Results 6Mindray Announces Second Quarter 2011 Financial Results 7Mindray Announces Second Quarter 2011 Financial Results 8Mindray Announces Second Quarter 2011 Financial Results 9Mindray Announces Second Quarter 2011 Financial Results 10Mindray Announces Second Quarter 2011 Financial Results 11Mindray Announces Second Quarter 2011 Financial Results 12Mindray Announces Second Quarter 2011 Financial Results 13Mindray Announces Second Quarter 2011 Financial Results 14Mindray Announces Second Quarter 2011 Financial Results 15Mindray Announces Second Quarter 2011 Financial Results 16Mindray Announces Second Quarter 2011 Financial Results 17K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 2K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 3K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 4K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 5K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 6K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 7K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 8
(Date:5/24/2015)... York (PRWEB) May 24, 2015 ... lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled its next ... of the multidistrict litigation. According to court documents ... of Illinois, the Conference will be convened on ... Testosterone Replacement Therapy Product Liability Litigation - MDL ...
(Date:5/24/2015)... Scottsdale, Arizona (PRWEB) May 24, 2015 ... hired former Millennial Media strategy executive Jay Krihak ... as Medicx looks to ramp up its expertise ... services of the Pharmaceutical and Health sectors. , ... ad tech executive. Most recently, Krihak led sales ...
(Date:5/23/2015)... 2015 On Saturday, May 23, 2015, over ... for Branches Florida City exactly five years to the day ... 2010. , A large fire tore through the Branches United ... 2010 in the middle of the night as neighbors, staff ... declared arson even though it is suspected that the fire ...
(Date:5/23/2015)... 23, 2015 With the implementation of ... finding it increasingly difficult to provide their employees with ... provide adequate insurance for employees stand to face strict ... an integral part of a business’s success or failure. ... businesses, Online USA Doctors has created a varying level ...
(Date:5/23/2015)... Manufacturers are now required to produce water heaters ... Experts in the field agree that the regulation is aimed ... score is what miles per gallon is to your car. ... the minimum HSPF score has been raised to 8.2, technology ... north of 12. Indeed, the regulation was welcomed by environmentalist, ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Medicx Media Solutions Expands Executive Team 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2
... Will Retire from the Lilly ... Board, ... LLY ) has elected Michael L. Eskew, former,chairman and chief executive officer ... Eskew will stand for election,by the shareholders at the 2008 annual meeting in ...
... Feb. 19 WeissComm Partners,the largest independent ... announced the appointment of Tom Jones as ... Corporation,where he was executive director of communications, ... relations programs for the,company,s growth driver brands. ...
... Nation,s 6th Best Hospital, DENVER, Feb. ... Board: GLOB), an international e-Health, medical,information technology ... has signed an agreement with NewYork-Presbyterian,Hospital (NYP), ... in the,world, to license its SafeTrace Tx(R) ...
... under control, researchers say , , TUESDAY, Feb. 19 (HealthDay ... blood pressure under control, and this may help explain ... pressure. , That,s just one of a series of ... of the journal Hypertension . The issue commemorates ...
... While Cutting Prices for,Existing Drugs, According to a ... Mass., Feb. 19 Decision Resources, Inc., one,of ... on,pharmaceutical and healthcare issues, finds that Japan has ... for 2008 and beyond.,The changes reflect the Japanese ...
... Feb. 19 Arcapita Inc., a leading private,equity investment ... its,affiliates have agreed to sell TLC Health Care Services, ... AMED ), for an enterprise value of,$395 million., ... York, TLC is the,largest privately-held home healthcare provider in ...
Cached Medicine News:Health News:Michael L. Eskew Elected to Lilly Board of Directors 2Health News:WeissComm Partners Names Tom Jones Managing Director to Deepen Global Product Communications Offering 2Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 2Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 3Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 4Health News:Hypertension a Health Challenge for Women 2Health News:Hypertension a Health Challenge for Women 3Health News:Japan Backs Away from Making Real Changes to Its Rx Pharma Pricing Mechanism 2Health News:Arcapita to Sell TLC Health Care Services, Inc. for $395 Million 2
... temporary internal drainage from the ureteropelvic junction ... stricture. The segment with no sideports prevents ... preventing ingrowth of the ureteral wall to ... Intended for one-time use. CAUTION: Periodic evaluation ...
Since first designed by Dr. Roy P. Finney in 1978, ACMI™ Classic Ureteral Stents remain the standard for comfort, performance, and quality....
... retrograde or antegrade ureteral ... stent placement. The RB ... band on the delivery ... fluoroscopic visualization during placement. ...
... Used for interoperative placement to ... conduit construction and continent urinary ... packages. Intended for one-time use. ... stent must not remain indwelling ...
Medicine Products: